IL17A and psoriasis: Furthermore, prior incidences of pembrolizumab-induced psoriasis resolved with IL-17 blockade7 and ixekizumab reportedly resolved a pembrolizumab-induced mixed psoriasiform, lichenoid, and spongiotic eruption.8